Shannon Thyme Klinger, Chief Legal Officer of Moderna, Inc. (NASDAQ:MRNA), reported multiple transactions in Moderna common stock and derivative securities on September 1, 2026, in a Form 4 filed with the SEC on September 3, 2026.
Key Highlights
- Option exercise: Klinger exercised a stock option for 3,471 shares of common stock at an exercise price of $30.96 per share on September 1, 2026.
- Shares sold: 3,471 shares of common stock were disposed of (transaction code S) at $139.95 per share on September 1, 2026, pursuant to a Rule 10b5-1 trading plan.
- RSU conversion: 2,166 restricted stock units converted into common stock on a one-for-one basis on September 1, 2026.
- Tax withholding: 1,048 shares were withheld at the election of the reporting person to satisfy tax withholding obligations in connection with the vest of restricted stock units, at $140.34 per share.
- Resulting ownership: Following all reported transactions, Klinger directly holds 75,247 shares of Moderna common stock.
- 10b5-1 plan: The option exercise and related share sale were made pursuant to a Rule 10b5-1 trading plan adopted on September 9, 2025.
Moderna CLO Reports Option Exercise, RSU Vest, and Share Transactions on September 1, 2026
According to the filing, Shannon Thyme Klinger, serving as Chief Legal Officer at Moderna, Inc., a biopharmaceutical company headquartered at 325 Binney Street, Cambridge, Massachusetts, reported a series of transactions in company securities. The filing indicates that Klinger exercised a stock option covering 3,471 shares at a conversion or exercise price of $30.96. The option, which carries an expiration date of March 1, 2035, had 25% vesting on March 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter, according to the explanation of responses.
The filing also discloses that 2,166 restricted stock units were converted into common stock on a one-for-one basis on September 1, 2026. Per the filing, 25% of the shares subject to the restricted stock unit award vested on March 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter. Separately, 1,048 shares were withheld at $140.34 per share to cover tax withholding obligations connected to the RSU vest. This withholding transaction carries transaction code F, as reported in Table I of the filing.
All transactions reported in Table I are classified as direct ownership. The filing was signed by James Dillon as Attorney-in-Fact on September 3, 2026. Following all reported transactions, the filing states Klinger directly holds 75,247 shares of Moderna common stock. The option exercise and the related disposition of shares were each noted as being effected pursuant to a Rule 10b5-1 trading plan that was adopted on September 9, 2025, according to the explanation of responses included in the filing.
What Was Disclosed
The Form 4 filed on September 3, 2026 discloses that Moderna's Chief Legal Officer, Shannon Thyme Klinger, exercised stock options, received RSU conversions, disposed of shares, and had shares withheld for taxes on September 1, 2026, resulting in direct beneficial ownership of 75,247 shares of common stock.




Please wait processing your request...